Sie sind hier: Startseite > News > Events > BioVaria 2009 to Showcase Top Licensing Opportunities from German Universities and Public Research Organisations
« Juli 2017 »
Juli
MoDiMiDoFrSaSo
12
3456789
10111213141516
17181920212223
24252627282930
31

Teaser biosaxony

Teaser biodeutschland

 

NEWS.
Events

 

BioVaria 2009 to Showcase Top Licensing Opportunities from German Universities and Public Research Organisations

Showcasing event to be held on May 8, 2009 in Munich, Germany Press Release

Wann 08.05.2009
from 09:00 to 18:00
Wo Sofitel Munich Bayerpost, Bayerstr. 12, 80335 Munich, Germany
Termin übernehmen vCal
iCal

March 10, 2009, Munich, Germany -- Ascenion and its partners are pleased to announce the forthcoming BioVaria 2009 to be held in Munich on May 8, 2009. Throughout one interactive day, inventors from a wide range of German universities and public research organisations will present selected projects with strong commercial prospects to delegates from the biopharmaceutical industry. Topics will cover research tools, therapeutics, platform technologies and diagnostics in the fields of cancer, inflammation, autoimmune, cardiovascular and other diseases.

BioVaria is the nation’s first biopharmaceutical showcasing event that integrates technology transfer organisations from all across Germany. Key features are:
 

  • Presentation of Germany’s top 50 patent-protected life science technologies
  • Interactive format combining 10-min presentations with an all-day poster exhibition
  • Ample space to discuss scientific details face-to-face with the inventors
  • Unique opportunity to exchange in-licensing needs with technology transfer professionals from a wide range of institutions and universities

This year’s keynote lecture: „Pharma 2020 – challenges to the pharma business model and the impact on cooperations“ by Dr Oliver Weyand, Senior Manager at PricewaterhouseCoopers AG.

When BioVaria was first held in May 2008, the event brought together over 150 delegates from public research and the international biopharmaceutical industry. The innovative format proved highly effective in promoting technology transfer. Many interactions that were initiated during BioVaria 2008 are still ongoing. Some projects are already in advanced stages of licensing negotiations, a first deal was closed and a further concrete outcome was published earlier this year: the foundation of the oncology start-up MBiotec (see press release from February 20, 2009).

For registration, further information and updates please visit the BioVaria website: www.biovaria.org

Early registration discount – save 20% by registering by March 20, 2009

BioVaria 2009 is organised by Ascenion and its partners Bayerische Patentallianz, Deutsches Krebsforschungszentrum (DKFZ), EMBLEM, Technology Transfer GmbH, Fraunhofer VLS, IP-Bewertungs AG, Max Planck Innovation GmbH, MediGate GmbH, National Genome Research Network and PROvendis GmbH.

The event gains support from the Bavarian Ministry of Economic Affairs, Infrastructure, Transport and Technology, TEVA, Fresenius Biotech, Hertin – IP Law Firm, IP-Bewertungs AG, LSP, Merck Serono, TVM Capital and Vossius & Partner.

Communication Partner is KONOCOM. Network Partner is BioM.

Contact
Dr Isabel von Korff
Ascenion GmbH
Tel.: +49 (0)89 318814-18
Email: korff@ascenion.de

Ascenion GmbH
Herzogstr. 64
80803 Munich
Germany

About Ascenion GmbH
Ascenion GmbH is an IP asset management company focused on the life sciences. Ascenion advises and supports public research institutions with regard to the protection and exploitation of their intellectual property (patents, know-how, materials), and initiates and mediates license agreements between research institutions and industry. The company places particular emphasis on coaching company founders and on active equity management. Ascenion was founded in 2001 as a 100% subsidiary of the Life-Science Foundation for the Promotion of Science and Research and has since acquired 13 research institutes in the Helmholtz and Leibniz Associations and also the Hanover Medical School as exclusive partners. Ascenion currently markets around 600 technologies on behalf of these institutes, and closes an average of about 60 agreements between research and industry per year. The team has also coached numerous spin-offs through their foundation and early growth and Ascenion holds equity in 17 of these companies. Ascenion’s headquarters are in Munich, with further offices in Berlin, Braunschweig, Hamburg, Hanover and Neuherberg.

Further information at www.ascenion.de

Press Release (pdf)
 

Artikelaktionen